News for 'Pharma'

Andhera Review: Absurd

Andhera Review: Absurd

Rediff.com14 Aug 2025

It is sporadically chilling but the disparate elements take forever to come together, notes Deepa Gahlot.

Sensex tanks 586 points on global sell-off

Sensex tanks 586 points on global sell-off

Rediff.com1 Aug 2025

Tata Steel, Maruti, Tata Motors, Infosys, Bharti Airtel and Tech Mahindra were also among the laggards. However, Trent, Asian Paints, Hindustan Unilever, ITC, Kotak Mahindra Bank, and Reliance Industries were the gainers.

Stock markets weather Trump tariff storm

Stock markets weather Trump tariff storm

Rediff.com7 Aug 2025

Among Sensex firms, Tech Mahindra, HCL Tech, Eternal, Axis Bank, Maruti, Tata Steel, HDFC Bank and Asian Paints were the gainers. However, Adani Ports, Trent, Tata Motors, Hindustan Unilever and NTPC were among the laggards.

Can India-US Tariff Issue Be Resolved Amicably?

Can India-US Tariff Issue Be Resolved Amicably?

Rediff.com28 Aug 2025

Communication channels between India and the US are open to resolve the ongoing tariff issues, and the glitch in trade ties is only temporary, given the long-term relationship between the two nations, government sources said on Wednesday. The US' 50 per cent tariffs on Indian exports to America came into effect from August 27, barring a few sectors.

India, US Push To Futureproof Trade Ties

India, US Push To Futureproof Trade Ties

Rediff.com29 Jul 2025

India is seeking either an exemption or a longer timeline on the pharmaceutical tariffs, expected to kick in by July 31.

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Rediff.com25 Jul 2025

Stock markets declined for the second day in a row on Friday, with the Sensex tumbling 721 points due to heavy selling in financial, IT and oil & gas shares amid persistent foreign fund outflows.

Why Stock Tips Won't Build Wealth For You

Why Stock Tips Won't Build Wealth For You

Rediff.com3 Sep 2025

Real wealth isn't built on random bets; it's built on disciplined, guided portfolio strategies that can withstand market ups and downs, says Ramalingam Kalirajan.

Buying in L&T helps Sensex gain 144 points

Buying in L&T helps Sensex gain 144 points

Rediff.com30 Jul 2025

Sun Pharma, NTPC, Maruti, Bharti Airtel, Trent and Axis Bank were also among the gainers. However, Tata Motors, Power Grid, Eternal, Bajaj Finserv and Hindustan Unilever were among the laggards.

Blue-chip stocks drag Sensex down by 542 points

Blue-chip stocks drag Sensex down by 542 points

Rediff.com24 Jul 2025

From the Sensex firms, Trent, Tech Mahindra, Bajaj Finserv, Reliance Industries, Infosys, Kotak Mahindra Bank, HCL Technologies, and NTPC were among the biggest laggards. However, Eternal, Tata Motors, Sun Pharma, Tata Steel, and Titan were the gainers.

Sensex pares losses, ends up 64 points

Sensex pares losses, ends up 64 points

Rediff.com16 Jul 2025

Among Sensex firms, Mahindra & Mahindra, Tech Mahindra, State Bank of India, Infosys, Adani Ports and ITC were the major gainers. However, Eternal, Sun Pharma, Tata Steel, Tata Motors, Bajaj Finance and Bharat Electronics were among the major laggards.

Apollo eyes 20-23% growth in new co; says restructuring to unlock value

Apollo eyes 20-23% growth in new co; says restructuring to unlock value

Rediff.com2 Jul 2025

Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly-formed entity is expected to achieve a year-on-year growth rate of 22-23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by the financial year 2027.

Govt to Monitor Non-Essential Drug Prices

Govt to Monitor Non-Essential Drug Prices

Rediff.com28 Jul 2025

The National Pharmaceutical Pricing Authority will monitor how companies are increasing prices of non-scheduled drugs.

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Rediff.com14 May 2025

A fresh US executive order (EO) which seeks to bring down prices of prescription drugs in the country by up to 90 per cent -- on par with other developed nations -- will affect innovator companies, while sparing the Indian generic drug makers in the short term. US President Donald Trump signed the EO on Monday, directing the US Trade Representative and the Secretary of Commerce to act against foreign countries that "purposefully and unfairly undercut market prices", driving price hikes in the US.

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Rediff.com23 Dec 2024

India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).

Indian pharma improves compliance with USFDA; fewer OAI cases in 2024

Indian pharma improves compliance with USFDA; fewer OAI cases in 2024

Rediff.com30 Dec 2024

Indian pharmaceutical companies have made major strides in adhering to stringent US Food and Drug Administration (USFDA) norms in 2024, with data suggesting a decline in the number of adverse classification outcomes of inspections across biologics, drugs, and devices. In 2023, the USFDA conducted 225 inspections, which led to 18 cases of Official Action Indicated (OAI) and 117 cases of Voluntary Action Indicated (VAI).

LIC's stock portfolio sees Rs 46,000 cr dent in July

LIC's stock portfolio sees Rs 46,000 cr dent in July

Rediff.com5 Aug 2025

Life Insurance Corporation (LIC) , the country's largest domestic institutional investor (DII), has seen a Rs 46,000 crore erosion in the value of its equity holdings amid market downturns in July. The benchmark indices, Nifty 50 and BSE Sensex, have slipped 2.6 per cent from their June 2025-end level to 24,837 and 81,463.09 respectively.

How the markets will fare this week

How the markets will fare this week

Rediff.com27 Jul 2025

Stock markets are in for an event-heavy week ahead with a raft of Q1 earnings from blue-chips, the US Fed interest rate decision and foreign investors trading activity driving investors' sentiment, analysts said. Macroeconomic data announcements, monthly auto sales numbers and global market trends would also guide movement in the domestic equities, they said.

Procter & Gamble names Shailesh Jejurikar as CEO

Procter & Gamble names Shailesh Jejurikar as CEO

Rediff.com29 Jul 2025

Procter & Gamble has announced Shailesh Jejurikar as its next CEO, effective January 1, 2026. Jejurikar, an India-born executive, will succeed Jon Moeller in the role.

Mankind Pharma to lead in Indian women's health market after BSV deal

Mankind Pharma to lead in Indian women's health market after BSV deal

Rediff.com29 Jul 2024

New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the Rs 13,630 crore deal to acquire Bharat Serums and Vaccines (BSV), senior company officials said. The deal potentially opens doors for Mankind Pharma to the overseas markets, which currently draws 92 per cent of its revenues from India. The combined entity will draw around 13 per cent revenues from the international market, with the remaining coming from the domestic market.

17 persons killed, 33 hurt in Andhra pharma unit fire

17 persons killed, 33 hurt in Andhra pharma unit fire

Rediff.com22 Aug 2024

Harrowing scenes unfolded at the SEZ where the fire ripped through the pharma company. Injured workers with torn clothes and bleeding injuries were seen being shifted to hospitals in ambulances.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Rediff.com11 Jun 2024

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

Trump Is Winning Tariff War Hands Down

Trump Is Winning Tariff War Hands Down

Rediff.com18 Aug 2025

Donald Trump's tariffs, meant as political punishment, have avoided the predicted chaos, lifting US growth, weakening rivals, and letting him claim victory in a resilient global economy, observes T T Ram Mohan.

Sensex decline on fag-end selling; financial stocks drag

Sensex decline on fag-end selling; financial stocks drag

Rediff.com3 Jul 2025

Among the Sensex firms, Kotak Mahindra Bank, Bajaj Finserv, Bajaj Finance, Adani Ports, Trent, State Bank of India, Titan and Tata Consultancy Services were the laggards. However, Maruti, Infosys, NTPC, Asian Paints, Eternal and Hindustan Unilever were among the biggest gainers.

Upper-teens EPS growth likely for Gland Pharma in next two financial yrs

Upper-teens EPS growth likely for Gland Pharma in next two financial yrs

Rediff.com13 Nov 2024

Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. However, overall Ebitda margin was better than expectations at 21.1 per cent. But given two years of earnings decline in FY23 and FY24, the business may have bottomed and upper-teens EPS (earnings per share) growth looks possible over next two financial years.

T'gana plant blast: 9 still missing; cause yet to be known

T'gana plant blast: 9 still missing; cause yet to be known

Rediff.com3 Jul 2025

Nine people remain missing following the explosion at the Sigachi Industries' pharma plant in Pashamylaram, Telangana, which claimed 38 lives. An expert committee is investigating the cause of the blast.

Trump's Tariffs: Why India Needs To Be Strategic

Trump's Tariffs: Why India Needs To Be Strategic

Rediff.com12 Aug 2025

In trade negotiations, as in chess, sometimes you need to accept a temporary disadvantage to secure a better long-term position, points out Sonal Varma, chief economist (India and Asia ex-Japan) at Nomura.

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Rediff.com17 Jun 2025

From the Sensex pack, Sun Pharma, Eternal, Tata Motors, Bajaj Finance, IndusInd Bank and Bajaj Finserv were among the major laggards. In contrast, Tech Mahindra, Infosys, Asian Paints and Maruti were among the gainers.

Sensex gains 320 points; Nifty ends above 24K

Sensex gains 320 points; Nifty ends above 24K

Rediff.com29 May 2025

Benchmark stock indices Sensex and Nifty rebounded on Thursday after two days of decline, mirroring a rally in global markets as a US court blocked President Donald Trump's reciprocal tariffs. The 30-share BSE Sensex climbed 320.70 points or 0.39 per cent to settle at 81,633.02.

Budget 2024: Wishlist of the pharma industry

Budget 2024: Wishlist of the pharma industry

Rediff.com8 Jul 2024

There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

Sigachi used old machinery despite requests to change, says FIR

Sigachi used old machinery despite requests to change, says FIR

Rediff.com2 Jul 2025

An FIR filed against Sigachi Industries following a fatal explosion at its Telangana unit alleges the company used outdated machinery despite warnings from employees.

Sensex, Nifty rebound nearly 1% on value buying

Sensex, Nifty rebound nearly 1% on value buying

Rediff.com16 Jun 2025

Among 30 Sensex firms, UltraTech Cement, Tech Mahindra, HCL Tech, Tata Consultancy Services, Eternal, Asian Paints, Tata Steel and Kotak Mahindra Bank were among the biggest gainers. Tata Motors, Adani Ports and Sun Pharma were the laggards.

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Rediff.com27 Jun 2025

From the Sensex pack, Asian Paints, UltraTech Cement, Power Grid, ICICI Bank, Reliance Industries, Hindustan Unilever, Bharat Electronics and Sun Pharma were among the major gainers. In contrast, Trent, Eternal, Axis Bank and Titan were among the laggards.

Key factors to drive stock markets this week

Key factors to drive stock markets this week

Rediff.com6 Jul 2025

Equity investors are up for an eventful trading week ahead as the 90-day suspension period of the reciprocal tariffs announced by US President Donald Trump ends on July 9, analysts said, adding that a positive outcome from the trade negotiations could further lift market sentiment, particularly benefiting trade-sensitive sectors.

Sensex drops 345 points on weakness in IT stocks

Sensex drops 345 points on weakness in IT stocks

Rediff.com10 Jul 2025

From the Sensex pack, Bharti Airtel, Asian Paints, Infosys, Bharat Electronics, Tech Mahindra and Eternal were major laggards. However, Maruti, Tata Steel, Bajaj Finance, Bajaj Finserv, Trent and Tata Consultancy Services were among the gainers.

'Will Learning AI Help Me As An Entrepreneur?'

'Will Learning AI Help Me As An Entrepreneur?'

Rediff.com28 May 2025

Dr Ganesh Natarajan, a special guest on rediffGURUS, has been addressing questions from Rediff readers, about how to grow professionally, how women can achieve leadership roles in Indian companies, and what it takes to succeed as an entrepreneur.

Foreign fund inflows, ICICI Bank and RIL boost markets

Foreign fund inflows, ICICI Bank and RIL boost markets

Rediff.com5 Jun 2025

Eternal was the biggest gainer in the Sensex pack, jumping 4.50 per cent, followed by Power Grid, ICICI Bank, Reliance Industries, UltraTech Cement, Adani Ports, Sun Pharma, ITC and Hindustan Unilever were also among the winners. In contrast, IndusInd Bank, Axis Bank, Bajaj Finserv and Bajaj Finance were among the laggards.

Sensex surges over 769 pts as FMCG, power shares gain

Sensex surges over 769 pts as FMCG, power shares gain

Rediff.com23 May 2025

From the Sensex firms, Eternal, Power Grid, ITC, Bajaj Finserv, Nestle, Axis Bank, Kotak Mahindra Bank and Adani Ports were among the biggest gainers. Sun Pharma was the only laggard, declining nearly 2 per cent.

Sensex sinks 573 pts on global tensions and high crude prices

Sensex sinks 573 pts on global tensions and high crude prices

Rediff.com13 Jun 2025

Sensex sinks 573 pts on global tensions and high crude prices

Weak Q4 may be rare bitter pill for Sun Pharma

Weak Q4 may be rare bitter pill for Sun Pharma

Rediff.com31 May 2024

Sun Pharmaceutical Industries reported a 34 per cent year-on-year (Y-o-Y) jump in net profit to Rs 2,654.6 crore in Q4FY24.

How Kerala Aims to Be India's First Poverty Free State

How Kerala Aims to Be India's First Poverty Free State

Rediff.com14 Jul 2025

Despite facing financial constraints, Kerala has been able to invest in welfare schemes and targeted programmes.